GLP Tirzepatide: What the Dual-Receptor Science Actually Means for Weight Loss

You've read that tirzepatide is 'like Ozempic but stronger', here's what the biology actually says

That description is everywhere, and it's only half right. Semaglutide (Wegovy) targets one receptor: GLP-1. Tirzepatide, sold in the UK as Mounjaro, targets two: GLP-1 and GIP. If you want to understand how tirzepatide engages the GLP-1 receptor and what that hormone actually does in the body, the science behind appetite signalling and blood sugar regulation is covered there in full. GIP is a separate incretin hormone that amplifies those effects and may act on fat tissue directly. Activating both pathways at once appears to produce a stronger appetite-suppressing effect than either pathway alone, which is why researchers and clinicians describe tirzepatide as a genuinely different mechanism, not simply a higher dose of the same idea.

If you want to read more about how the GIP side of this equation works, our page on tirzepatide's GLP-1 and GIP dual action covers the receptor science in more detail, including what happens when tirzepatide's activity at the GIP receptor is added into the picture. The NHS's own tirzepatide medicine page also summarises how the drug works, in plain language written for patients.

What this means practically: people on tirzepatide tend to feel full on smaller portions and find that the drive to eat between meals reduces. That's biology, not willpower, a distinction the clinical evidence is making increasingly hard to ignore.

What the trial data shows, and how to read it honestly

The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled 2,539 adults with obesity who did not have type 2 diabetes. At 72 weeks, average weight loss at the 15 mg dose was around 20–21% of body weight. That is a large effect by any historical comparison for a non-surgical intervention. NICE, in its appraisal of tirzepatide (TA1026), noted that indirect comparisons favoured tirzepatide over semaglutide 2.4 mg, a finding later reinforced by the head-to-head SURMOUNT-5 trial published in 2025.

A few things to hold alongside those numbers. First, trials measure averages; individual responses vary. Second, participants followed a reduced-calorie diet and increased their activity alongside injections, the medicine works with lifestyle changes, not instead of them. Third, the 15 mg dose is a maintenance dose reached after several months of titration; most people start at 2.5 mg, a level designed to let the body adjust before the dose climbs.

For context on how Mounjaro's private cost fits into this picture, our page on Eli Lilly's UK price changes explains the market background honestly, including what happened to list prices from September 2025.

Who the licence covers, and what a prescriber looks at beyond BMI

Tirzepatide holds a UK licence for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnoea or cardiovascular disease. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. NICE recommends it on the NHS for adults with a BMI of at least 35 plus one or more qualifying comorbidities, under phased eligibility criteria that are expanding through 2025 to 2027.

Private prescribing follows the licensed indications, but BMI alone is never the whole assessment. A prescriber looks at your current medicines, any conditions that would make tirzepatide unsuitable (certain thyroid conditions, a history of pancreatitis, specific gastrointestinal disorders), your goals, and whether this is the right moment in your health journey for this kind of treatment. It is that conversation (not a checklist) that determines suitability. You can read more about the broader treatment landscape on our weight loss overview, or explore the tirzepatide treatment page for a fuller picture of the medicine itself.

If you're weighing up whether to start, or wondering whether your situation is typical, that uncertainty is entirely normal. Most people arrive at this decision after months of thinking.

Side effects, safety monitoring and the MHRA's role

The most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion, bloating, reduced appetite. These tend to be most noticeable in the first week or two after starting or after a dose increase, and they usually settle. Keeping meals small, staying hydrated and eating slowly all help.

Less common but more serious: pancreatitis has been identified as an infrequent but potentially serious risk with GLP-1 class medicines. The MHRA issued a Drug Safety Update on this in January 2026, advising that severe or persistent stomach pain (particularly if it spreads to the back) warrants urgent medical attention. Tirzepatide carries the Black Triangle (▼) symbol, meaning the MHRA continues to collect additional safety data on it. Patients and clinicians can report suspected side effects via the Yellow Card scheme.

For women using oral contraceptives, the prescriber may advise adding a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide can slow the absorption of oral medicines. NHS guidance also suggests considering transdermal HRT for the same reason. These are not reasons to avoid the medicine; they are things the prescriber factors into your plan.

If you'd like to speak to a clinician directly about whether tirzepatide is suitable for your situation, you can start your free consultation with a GPhC-registered prescriber at nume, a real person reads your answers the same day.